Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Total Current Liabilities (2016 - 2025)

BioCorRx's Total Current Liabilities history spans 16 years, with the latest figure at $15.0 million for Q3 2025.

  • For Q3 2025, Total Current Liabilities rose 82.85% year-over-year to $15.0 million; the TTM value through Sep 2025 reached $15.0 million, up 82.85%, while the annual FY2024 figure was $8.2 million, 27.62% up from the prior year.
  • Total Current Liabilities for Q3 2025 was $15.0 million at BioCorRx, up from $14.6 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $15.0 million in Q3 2025 and bottomed at $2.8 million in Q2 2021.
  • The 5-year median for Total Current Liabilities is $5.9 million (2023), against an average of $7.1 million.
  • The largest annual shift saw Total Current Liabilities dropped 21.03% in 2021 before it soared 99.03% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $4.4 million in 2021, then grew by 22.28% to $5.4 million in 2022, then grew by 19.9% to $6.4 million in 2023, then increased by 27.62% to $8.2 million in 2024, then skyrocketed by 83.22% to $15.0 million in 2025.
  • Per Business Quant, the three most recent readings for BICX's Total Current Liabilities are $15.0 million (Q3 2025), $14.6 million (Q2 2025), and $13.4 million (Q1 2025).